Hypertonic Saline as a Final Flush and Post-Operative Pain After Single Visit Root Canal Treatment in Mandibular Premolar. (Hypertonic)
Effect of Hypertonic Saline (3%) as a Final Flush Irrigant on Post-Operative Pain and Substance P Expression Following Single-Visit Root Canal Treatment in Patients With Symptomatic Irreversible Pulpitis Related to Mandibular Premolars: A Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Kariman Ameen Ismaiel
- Phone Number: +201013665586
- Email: kariman.ameen@dentistry.cu.edu.eg
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-60 years, any sex
- Systemically healthy
- Mandibular premolar with clinically/radiographically diagnosed symptomatic irreversible pulpitis (prolonged, exaggerated response to cold testing; no periapical radiolucency)
- Able to use the VAS scale and complete follow-up
Exclusion Criteria:
- Medically compromised patients
- Pregnant or lactating women
- Allergy/hypersensitivity to local anesthetics or NSAIDs
- Analgesics, anti-inflammatories, or antibiotics within 12 hours pre-treatment
- Vertical root fracture, root resorption, or previous RCT
- Radiographic periapical pathology
- Non-restorable teeth
- TMD, bruxism, or traumatic occlusion interfering with pain assessment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Normal Saline 0.09
Isotonic, biologically inert final irrigant; mechanical debridement only, no pharmacological activity.
|
Isotonic 0.9% NaCl solution used as final canal flush, no pharmacological activity
|
|
Experimental: Hypertonic Saline 3%
Isotonic, biologically inert final irrigant; mechanical debridement only, no pharmacological activity.
|
Osmotic/anti-inflammatory final irrigant hypothesized to reduce periapical edema and suppress pro-inflammatory cytokine-mediated SP release via NF-κB pathway inhibition.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-operative pain intensity at 6 hours
Time Frame: 6 hours post-operatively
|
Visual Analogue Scale (VAS), 0-10 (0 = no pain, 1-3 mild, 4-6 moderate, 7-10 severe)
|
6 hours post-operatively
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-operative pain intensity at 12, 24, and 48 hours
Time Frame: 12, 24, and 48 hours post-operatively
|
VAS, 0-10, same categorization as primary
|
12, 24, and 48 hours post-operatively
|
|
Change in periapical Substance P expression (ΔSP = S2 - S1)
Time Frame: S1 = after working length determination (intra-operative); S2 = immediately after final flush (intra-operative)
|
Quantified by ELISA (human Substance P kit) from periapical fluid collected via paper point; pg/mL
|
S1 = after working length determination (intra-operative); S2 = immediately after final flush (intra-operative)
|
|
Number of rescue analgesic tablets consumed
Time Frame: 24 and 48 hours post-operatively
|
Ibuprofen 400 mg tablets, patient-recorded tablet-count chart, max 3 tablets/24 h
|
24 and 48 hours post-operatively
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ENDO 3.3.3
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.